Analysts Set Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) PT at $57.80

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) have been assigned an average recommendation of "Buy" from the nine ratings firms that are presently covering the stock, Marketbeat reports. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $53.50.

Several equities analysts have weighed in on ARCT shares. Wall Street Zen upgraded shares of Arcturus Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Citigroup restated a "buy" rating on shares of Arcturus Therapeutics in a report on Tuesday, May 13th. HC Wainwright reissued a "buy" rating and issued a $60.00 price objective on shares of Arcturus Therapeutics in a research report on Thursday, April 10th. Scotiabank started coverage on shares of Arcturus Therapeutics in a research note on Wednesday. They set a "sector outperform" rating and a $32.00 price target for the company. Finally, Canaccord Genuity Group reduced their target price on shares of Arcturus Therapeutics from $68.00 to $66.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th.

Arcturus Therapeutics Stock Performance

NASDAQ ARCT traded down $0.09 on Friday, reaching $11.94. 142,189 shares of the company's stock traded hands, compared to its average volume of 449,698. The firm has a market cap of $323.82 million, a price-to-earnings ratio of -5.38 and a beta of 2.36. The stock has a 50 day moving average price of $11.33 and a 200-day moving average price of $14.90. Arcturus Therapeutics has a fifty-two week low of $8.04 and a fifty-two week high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($0.52) earnings per share for the quarter, beating analysts' consensus estimates of ($1.58) by $1.06. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The company had revenue of $29.38 million during the quarter, compared to analysts' expectations of $25.64 million. As a group, equities research analysts anticipate that Arcturus Therapeutics will post -2.22 EPS for the current fiscal year.

Institutional Investors Weigh In On Arcturus Therapeutics

Several hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP boosted its position in shares of Arcturus Therapeutics by 0.8% in the fourth quarter. Wellington Management Group LLP now owns 97,036 shares of the biotechnology company's stock worth $1,647,000 after acquiring an additional 742 shares during the last quarter. Ameriprise Financial Inc. lifted its position in Arcturus Therapeutics by 5.0% during the fourth quarter. Ameriprise Financial Inc. now owns 18,613 shares of the biotechnology company's stock valued at $316,000 after buying an additional 883 shares in the last quarter. Tocqueville Asset Management L.P. lifted its position in Arcturus Therapeutics by 4.5% during the first quarter. Tocqueville Asset Management L.P. now owns 23,400 shares of the biotechnology company's stock valued at $248,000 after buying an additional 1,000 shares in the last quarter. Virtus ETF Advisers LLC lifted its position in Arcturus Therapeutics by 38.8% during the fourth quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company's stock valued at $69,000 after buying an additional 1,132 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in Arcturus Therapeutics by 9.2% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 14,693 shares of the biotechnology company's stock valued at $156,000 after buying an additional 1,232 shares in the last quarter. 94.54% of the stock is owned by institutional investors and hedge funds.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.